Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals

Drug Profile

Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals

Alternative Names: Angeliq; Angeliq Low Dose; Angeliq low-low; BAY-864891; E2+DRSP; E2-DRSP; Estradiol/drospirenone

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Class Androstenes; Antiandrogens; Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Aldosterone antagonists; Estrogen receptor agonists; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis
  • Discontinued Contraception; Hypertension

Most Recent Events

  • 02 Feb 2015 Discontinued - Phase-II for Contraception in Germany (PO)
  • 02 Feb 2015 Launched for Menopausal syndrome in Switzerland, Mexico, Chile, Brazil, Argentina, Russia, Ukraine, Indonesia, Hong Kong, Thailand, Malaysia, Turkey, Israel, China, Canada, Australia and Philippines (PO)
  • 02 Feb 2015 Launched for Postmenopausal osteoporosis (Prevention) in Switzerland, Mexico, Chile, Brazil, Argentina, Russia, Ukraine, Indonesia, Hong Kong, Thailand, Malaysia, Turkey and Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top